"The iCTC manufacturing center in Philadelphia is really what is setting Iovance apart from other cell therapy companies that still farm out production. All lifileucel manufacturing runs through that single internalized facility, with capacity for up to 5,000 patients per year and a turnaround time of 32 days or less."
"Q4 revenue hit $86.71 million, up 17.7% year-over-year and roughly 30% sequentially, driven by Amtagvi, the first FDA-approved T-cell therapy for solid tumors. Gross margin reached 50% in Q4, up from 38.2% a year earlier. The per-share loss narrowed to -$0.18 from -$0.26."
"COO Igor Bilinsky described it as capable of providing 'uninterrupted supply and fully support anticipated global demand today and scale up for the future even during future annual maintenance periods.' That structural cost advantage is already flowing through the margin line."
Iovance Biotherapeutics experienced significant growth following Q4 2025 earnings, with stock price surging 43% and Reddit sentiment reaching 86/100. Q4 revenue reached $86.71 million, up 17.7% year-over-year and 30% sequentially, driven by Amtagvi, the first FDA-approved T-cell therapy for solid tumors. Gross margin improved to 50% from 38.2% year-over-year, while per-share losses narrowed to -$0.18 from -$0.26. Full-year 2025 revenue totaled $263.5 million, a 60.6% increase within guidance. The company's competitive advantage stems from its Philadelphia iCTC manufacturing facility, which internalizes all lifileucel production with capacity for 5,000 patients annually and 32-day turnaround times, providing structural cost advantages reflected in improving margins.
#biotherapeutics #cell-therapy-manufacturing #commercial-growth #fda-approved-therapeutics #competitive-moat
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]